Home LiteratureArticle Details
PMID: 24442106 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Smoking, p53 mutation, and lung cancer.

Molecular cancer research : MCR ·Vol. 12 ·No. 1 ·2014-01-00 ·Pages 3-13

Gibbons DL, Byers LA, Kurie JM

Abstract

This issue marks the 50th anniversary of the release of the U.S. Surgeon General's Report on Smoking and Health. Perhaps no other singular event has done more to highlight the effects of smoking on the development of cancer. Tobacco exposure is the leading cause of cancers involving the oral cavity, conductive airways, and the lung. Owing to the many carcinogens in tobacco smoke, smoking-related malignancies have a high genome-wide burden of mutations, including in the gene encoding for p53. The p53 protein is the most frequently mutated tumor suppressor in cancer, responsible for a range of critical cellular functions that are compromised by the presence of a mutation. Herein, we review the epidemiologic connection between tobacco exposure and cancer, the molecular basis of p53 mutation in lung cancer, and the normal molecular and cellular roles of p53 that are abrogated during lung tumor development and progression as defined by in vitro and in vivo studies. We also consider the therapeutic potential of targeting mutant p53 in a clinical setting based upon the cellular role of mutant p53 and data from genetic murine models.

MeSH Terms
Animals DNA Damage/genetics Disease Progression Humans Lung/pathology Lung Neoplasms/chemically induced,genetics Mice Mutation/genetics Smoking/adverse effects Tobacco/adverse effects Tumor Suppressor Protein p53/genetics
Chemicals
Tumor Suppressor Protein p53
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Gibbons Don L
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 0432, Houston, Texas 77030. dlgibbon@mdanderson.org.
Byers Lauren A
Kurie Jonathan M
References (96)
96 references, click to expand
  1. Suppression of lung adenocarcinoma progression by Nkx2-1.
    Nature. 2011 May 5;473(7345):101-4 PMID: 21471965
  2. Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung.
    N Engl J Med. 1987 Oct 29;317(18):1109-13 PMID: 2821398
  3. The p53 proto-oncogene can act as a suppressor of transformation.
    Cell. 1989 Jun 30;57(7):1083-93 PMID: 2525423
  4. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
    Nature. 2007 Feb 8;445(7128):656-60 PMID: 17251933
  5. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
    Science. 1990 Nov 30;250(4985):1233-8 PMID: 1978757
  6. Stage-specific sensitivity to p53 restoration during lung cancer progression.
    Nature. 2010 Nov 25;468(7323):572-5 PMID: 21107428
  7. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.
    Nature. 2009 Nov 5;462(7269):104-7 PMID: 19847165
  8. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.
    Cancer Res. 2001 Sep 1;61(17):6350-5 PMID: 11522624
  9. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Nature. 1992 Mar 19;356(6366):215-21 PMID: 1552940
  10. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Nature. 2013 Jul 11;499(7457):214-218 PMID: 23770567
  11. Cooperative tumorigenic effects of germline mutations in Rb and p53.
    Nat Genet. 1994 Aug;7(4):480-4 PMID: 7951317
  12. Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functions.
    PLoS Genet. 2013;9(8):e1003726 PMID: 23966881
  13. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
    Mol Cell Biol. 2001 Mar;21(5):1874-87 PMID: 11238924
  14. The differential effects of mutant p53 alleles on advanced murine lung cancer.
    Cancer Res. 2005 Nov 15;65(22):10280-8 PMID: 16288016
  15. Genomic landscape of non-small cell lung cancer in smokers and never-smokers.
    Cell. 2012 Sep 14;150(6):1121-34 PMID: 22980976
  16. Selective activation of p53-mediated tumour suppression in high-grade tumours.
    Nature. 2010 Nov 25;468(7323):567-71 PMID: 21107427
  17. Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi.
    Science. 1976 Dec 3;194(4269):1067-9 PMID: 982061
  18. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations.
    Mol Cancer Res. 2013 Jun;11(6):638-50 PMID: 23449933
  19. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.
    Nature. 1984 Dec 13-19;312(5995):646-9 PMID: 6095116
  20. Restoration of p53 function leads to tumour regression in vivo.
    Nature. 2007 Feb 8;445(7128):661-5 PMID: 17251932
  21. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.
    Nat Med. 2002 Mar;8(3):282-8 PMID: 11875500
  22. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
    J Thorac Oncol. 2010 Jun;5(6):810-7 PMID: 20521348
  23. Database of p53 gene somatic mutations in human tumors and cell lines.
    Nucleic Acids Res. 1994 Sep;22(17):3551-5 PMID: 7937055
  24. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.
    J Clin Invest. 2011 Mar;121(3):893-904 PMID: 21285512
  25. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.
    Mol Cell Biol. 1999 Feb;19(2):1438-49 PMID: 9891077
  26. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells.
    Cell. 1979 May;17(1):43-52 PMID: 222475
  27. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.
    PLoS One. 2009;4(4):e5401 PMID: 19404390
  28. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Science. 2004 Feb 6;303(5659):844-8 PMID: 14704432
  29. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression.
    Genes Dev. 2009 Sep 15;23(18):2140-51 PMID: 19759262
  30. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers.
    Oncogene. 2002 Oct 21;21(48):7435-51 PMID: 12379884
  31. p53 status and the efficacy of cancer therapy in vivo.
    Science. 1994 Nov 4;266(5186):807-10 PMID: 7973635
  32. T antigen is bound to a host protein in SV40-transformed cells.
    Nature. 1979 Mar 15;278(5701):261-3 PMID: 218111
  33. Biochemical and morphological effects of cigarette smoke condensate and its fractions on normal human bronchial epithelial cells in vitro.
    Cancer Res. 1987 Apr 15;47(8):2045-9 PMID: 3828994
  34. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression.
    J Clin Invest. 2012 Sep;122(9):3170-83 PMID: 22850877
  35. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.
    Nature. 2001 Apr 26;410(6832):1111-6 PMID: 11323676
  36. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
    Clin Cancer Res. 2000 Oct;6(10):4055-63 PMID: 11051256
  37. Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice.
    Am J Physiol Lung Cell Mol Physiol. 2006 May;290(5):L931-45 PMID: 16361358
  38. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.
    Cancer Cell. 2005 Apr;7(4):363-73 PMID: 15837625
  39. A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells.
    Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6693-7 PMID: 1323115
  40. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation.
    Cancer Cell. 2010 Jan 19;17(1):89-97 PMID: 20129250
  41. Mutations in the p53 gene occur in diverse human tumour types.
    Nature. 1989 Dec 7;342(6250):705-8 PMID: 2531845
  42. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  43. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes.
    Cancer Res. 1988 Apr 1;48(7):1904-9 PMID: 2450641
  44. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
    Nature. 2012 Mar 18;483(7391):613-7 PMID: 22425996
  45. p53 mutations in cancer.
    Nat Cell Biol. 2013 Jan;15(1):2-8 PMID: 23263379
  46. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.
    Nat Genet. 1995 Mar;9(3):305-11 PMID: 7773294
  47. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.
    Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6302-7 PMID: 18424558
  48. Smoking and lung cancer: a statement of the Public Health Service.
    J Am Med Assoc. 1959 Nov 28;171:1829-37 PMID: 13806231
  49. p53: a frequent target for genetic abnormalities in lung cancer.
    Science. 1989 Oct 27;246(4929):491-4 PMID: 2554494
  50. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.
    Mol Cell Biol. 1989 Sep;9(9):3982-91 PMID: 2476668
  51. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53.
    Genes Dev. 1998 Jul 15;12(14):2102-7 PMID: 9679054
  52. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.
    Cell. 1993 Sep 24;74(6):957-67 PMID: 8402885
  53. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Cancer Res. 2012 Nov 1;72(21):5576-87 PMID: 22964582
  54. Another fork in the road--life or death decisions by the tumour suppressor p53.
    EMBO Rep. 2013 May;14(5):414-21 PMID: 23588418
  55. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice.
    J Clin Invest. 2011 Apr;121(4):1373-85 PMID: 21403400
  56. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.
    Cell. 1993 Sep 10;74(5):813-22 PMID: 8374952
  57. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.
    Cancer Res. 2011 Dec 15;71(24):7670-82 PMID: 21987723
  58. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.
    Cancer Cell. 2003 Sep;4(3):181-9 PMID: 14522252
  59. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice.
    Oncogene. 1994 Dec;9(12):3731-6 PMID: 7970733
  60. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.
    Cancer Discov. 2011 Aug;1(3):236-47 PMID: 21874163
  61. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
    Cancer Res. 2006 Feb 15;66(4):2116-28 PMID: 16489012
  62. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Oncogene. 1990 Oct;5(10):1603-10 PMID: 1979160
  63. Research on smoking and lung cancer: a landmark in the history of chronic disease epidemiology.
    Yale J Biol Med. 1990 Jan-Feb;63(1):29-46 PMID: 2192501
  64. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
    Cell. 2004 Dec 17;119(6):847-60 PMID: 15607980
  65. Regulation of p53 stability by Mdm2.
    Nature. 1997 May 15;387(6630):299-303 PMID: 9153396
  66. An oncogene-induced DNA damage model for cancer development.
    Science. 2008 Mar 7;319(5868):1352-5 PMID: 18323444
  67. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence.
    Cell. 2012 Jun 8;149(6):1269-83 PMID: 22682249
  68. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage.
    Nature. 2002 Apr 4;416(6880):560-4 PMID: 11932750
  69. Smoking and carcinoma of the lung; preliminary report.
    Br Med J. 1950 Sep 30;2(4682):739-48 PMID: 14772469
  70. A genetic mouse model for metastatic lung cancer with gender differences in survival.
    Oncogene. 2007 Oct 18;26(48):6896-904 PMID: 17486075
  71. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.
    Nat Med. 1996 Sep;2(9):985-91 PMID: 8782455
  72. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins.
    Cancer Res. 2004 Dec 15;64(24):9027-34 PMID: 15604268
  73. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000.
    J Natl Cancer Inst. 2012 Apr 4;104(7):541-8 PMID: 22423009
  74. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
    J Clin Oncol. 2001 Mar 15;19(6):1750-8 PMID: 11251006
  75. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
    Cell. 2004 Dec 17;119(6):861-72 PMID: 15607981
  76. Tobacco smoke carcinogens and lung cancer.
    J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210 PMID: 10413421
  77. p53 post-translational modification: deregulated in tumorigenesis.
    Trends Mol Med. 2010 Nov;16(11):528-36 PMID: 20932800
  78. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases.
    J Am Med Assoc. 1950 May 27;143(4):329-36 PMID: 15415260
  79. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells.
    Cancer Res. 2011 Apr 15;71(8):3087-97 PMID: 21363915
  80. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.
    Genes Dev. 2001 Dec 15;15(24):3243-8 PMID: 11751630
  81. Comprehensive genomic characterization of squamous cell lung cancers.
    Nature. 2012 Sep 27;489(7417):519-25 PMID: 22960745
  82. Temporal dissection of p53 function in vitro and in vivo.
    Nat Genet. 2005 Jul;37(7):718-26 PMID: 15924142
  83. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.
    Cancer Cell. 2012 Jun 12;21(6):793-806 PMID: 22698404
  84. Clonal growth of epithelial cells from normal adult human bronchus.
    Cancer Res. 1981 Jun;41(6):2294-304 PMID: 7016311
  85. MEDICAL Research Council's statement on tobacco smoking and cancer of the lung.
    Lancet. 1957 Jun 29;272(6983):1345-7 PMID: 13440048
  86. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
    J Clin Oncol. 2012 Oct 10;30(29):3633-9 PMID: 22965953
  87. Mdm2 promotes the rapid degradation of p53.
    Nature. 1997 May 15;387(6630):296-9 PMID: 9153395
  88. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors.
    Am J Respir Cell Mol Biol. 1998 Feb;18(2):188-96 PMID: 9476905
  89. Tumour angiogenesis regulation by the miR-200 family.
    Nat Commun. 2013;4:2427 PMID: 24018975
  90. Genetic mechanisms of tumor suppression by the human p53 gene.
    Science. 1990 Dec 14;250(4987):1576-80 PMID: 2274789
  91. Modes of p53 regulation.
    Cell. 2009 May 15;137(4):609-22 PMID: 19450511
  92. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
    J Clin Oncol. 2007 Nov 20;25(33):5240-7 PMID: 18024870
  93. Increased expression of mutant forms of p53 oncogene in primary lung cancer.
    Lancet. 1990 Mar 24;335(8691):675-9 PMID: 1969059
  94. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis.
    Cell Death Differ. 2012 Dec;19(12):1992-2002 PMID: 22790872
  95. Long-term organ culture of human bronchial epithelium.
    Cancer Res. 1976 Mar;36(3):1003-10 PMID: 1253162
  96. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene.
    Oncogene. 2001 Oct 4;20(45):6551-8 PMID: 11641780
Article Info
Journal
Molecular cancer research : MCR
Abbr.
Mol Cancer Res
ISSN
1557-3125
Published
2014-01-00
Pages
3-13
Language
English
Region
United States
NLM ID
101150042
PMCID
PMC3925633
Subset
IM
Grants
NCI NIH HHS · K08 CA151651 · United States
NCI NIH HHS · P30 CA016672 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com